Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children

Version 1 : Received: 7 September 2023 / Approved: 7 September 2023 / Online: 8 September 2023 (02:55:35 CEST)

A peer-reviewed article of this Preprint also exists.

Pérez-Nicado, R.; Massa, C.; Rodríguez-Noda, L.M.; Müller, A.; Puga-Gómez, R.; Ricardo-Delgado, Y.; Paredes-Moreno, B.; Rodríguez-González, M.; García-Ferrer, M.; Palmero-Álvarez, I.; Garcés-Hechavarría, A.; Rivera, D.G.; Valdés-Balbín, Y.; Vérez-Bencomo, V.; García-Rivera, D.; Seliger, B. Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children. Vaccines 2023, 11, 1636. Pérez-Nicado, R.; Massa, C.; Rodríguez-Noda, L.M.; Müller, A.; Puga-Gómez, R.; Ricardo-Delgado, Y.; Paredes-Moreno, B.; Rodríguez-González, M.; García-Ferrer, M.; Palmero-Álvarez, I.; Garcés-Hechavarría, A.; Rivera, D.G.; Valdés-Balbín, Y.; Vérez-Bencomo, V.; García-Rivera, D.; Seliger, B. Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children. Vaccines 2023, 11, 1636.

Abstract

(1) Background: SARS-CoV-2 infection is mostly accompanied by mild COVID-19 symptoms in children. However, the multisystem inflammatory syndrome (MIS-C) and long-term sequelae are often severe complications. Therefore, the protection of the pediatric population against SARS-CoV-2 with effective vaccines is particularly important. Here we compare the humoral and cellular immune responses elicited in children (n=15) aged 5-11 years vaccinated with RBD-based vaccines combined in a heterologous scheme of SOBERANA® 02 and SOBERANA® Plus with those from children (n=10) aged 4-11 years who recovered from mild symptomatic COVID-19. (2) Methods: Blood samples were taken 14 days after last dose for vaccinated and 45-60 days after the infection diagnosis for COVID-19 recovered children. Anti-RBD IgG and ACE2-RBD inhibition were assessed by ELISA; IgA, cytokine and cytotoxic related proteins profile were determined by multiplex assays. Total B and T cell subpopulations and IFN-γ release were measured by multiparametric flow cytometry using a large panel of antibodies after in vitro stimulation with S1 peptides. (3) Results: Significant higher levels of specific anti-RBD IgG and IgA and ACE2-RBD inhibition capacity were found in vaccinated children in comparison to COVID-19 recovered children. Th1-like and Th2-like CD4+ T cells were also significantly higher in vaccinated subjects. IFN-γ secretion were higher in central memory CD4+ T cells of COVID-19 recovered children, but no differences between both groups were found in CD4+ and CD8+ T cells effector, terminal and naïve T cell subpopulations. High levels of IL-2, IL-6, IFN-γ and IL-10 in contrast to low levels of IL-4 suggesting a predominant Th1 cell polarization. Cytotoxic-related proteins granzyme A and B, perforin and granulin were also found in the supernatant after S1 stimulation in both vaccinated and recovered children. (4) Conclusions: Vaccination with the heterologous scheme of SOBERANA® 02/ SOBERANA® Plus induces strong antibody and cellular immune response compared to natural infections of young children.

Keywords

SARS-CoV-2; COVID-19; Vaccine; Children; SARS-CoV-2 RBD IgG; Memory T cell

Subject

Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.